misfitS pOLITICS

We talk. We write. We entertain. Or so we think.
  • Home
  • Misfit Migrants
  • Mess Hall
  • Meet The Misfits
  • Misc. Musings
  • Home
  • Misfit Migrants
  • Mess Hall
  • Meet The Misfits
  • Misc. Musings

A Case For Patent Reform

8/6/2016

1 Comment

 
Mo
Drug prices are too high. Americans spend an average of about $1000 per year on prescription drugs.  And some prescription drugs cost thousands of dollars a month. There are some good reasons for this. It’s costly to develop effective drugs and get them through the FDA approval process.  Many more pharma R&D projects fail than succeed, and pharma companies need the profits from successful drugs to support R&D in developing new drugs. But prescription drugs are, no doubt, a significant driver of high healthcare costs.

People have offered a variety of proposals to address this problem, many of which involve a measure of top-down price control.  Price-control-based solutions are far from ideal. Most importantly, they quash the incentive to innovate by lowering pharma companies’ profits.  Simplifying the FDA approval process is a better way to help reduce drug prices, but more is required—patent reform, specifically.  

Patent rights are important property rights. The Founders understood this and provided Congress the power in Article I of the Constitution to grant patent rights to promote innovation. Patents provide an incentive to innovate by giving the inventor the opportunity to profit from his invention while excluding others from practicing it.  

Patent rights play a critical role in pharma, among other industries, because they protect truly innovative new drugs and provide incentives to develop them. But they also stifle competition by granting a right to exclude others from marketing competing drugs and stifle innovation by granting a right to exclude others from using the invention to develop other, related drug products. In addition, pharma patents often don’t cover new drugs or truly new uses for those drugs. Instead they cover minor, obvious improvements to or variations on old drugs that have been on the market for decades. So, branded companies have an incentive to use their profits on R&D for these product-line extensions rather than on new drug therapies.  

​Simply put, pharma patents keep the cost of medications high.  More competition is needed, primarily in the form of generic drugs, which are as safe and effective as branded drugs and compete directly with branded drugs, driving down drug prices.

So, how do we promote both innovation and competition at the same time? By reforming patent laws so it’s easier to invalidate patents. Right now, pharma patents are relatively easy to get and relatively hard to invalidate or design around. In the patent office, it’s just the inventor and a patent examiner having a back and forth about whether the invention is patentable. The patent examiner is, in theory, supposed to be pushing back on the inventor to make sure there’s really an invention. But patent examiners have huge case loads and have to rely quite a bit on the inventor being forthright about what has and hasn’t been done before.  


Once the patent is granted, it’s up to competitors like generic drug companies to try to get around the patents in court. The burden is high—too high. Patents exit the patent office with a presumption of validity, and patent challengers face a higher burden of proof than just the “preponderance of the evidence” standard in ordinary civil cases.  


The system of granting and reviewing patents needs to change. The standards to get patents should be higher, and the standards to invalidate patents should be lower. Both of these can be accomplished through changes to the Patent Act, for example, by eliminating the higher standard of proof in patent cases, by requiring the support to obtain a patent to be stronger, by loosening up restrictions on what can be used to show that an invention is really just an obvious variant of what was known, and by enabling a more adversarial process in the patent office before a patent is granted. These changes would enable generic drug companies to bring more competition to the market by lowering the most significant barrier to entry, and thereby bring down the cost of prescription drugs in a market-friendly way.
1 Comment
RW Nutjob
8/1/2017 03:01:08 pm

Excellent Mo.
I agree that price controls are top-down & stifle competition. One more factor in pricing of US drugs is price control in Canada. That puts pressure on Pharma's profit in the US. We are partially making up for Canada's price controlled drugs.

Reply



Leave a Reply.

    Misfits

    Just a gaggle of people from all over who have similar interests and loud opinions mixed with a dose of humor. We met on Twitter.
    ​Enough said.

    (If that's not enough, you can learn more here)

    Tweets by misfitspolitics

    Archives

    December 2021
    October 2021
    September 2021
    January 2021
    September 2020
    June 2020
    May 2020
    April 2020
    February 2020
    January 2020
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    April 2019
    March 2019
    February 2019
    December 2018
    November 2018
    October 2018
    September 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016

    Categories

    All
    2016
    9/11
    Abortion
    AFB
    Afghanistan
    Air Force
    #alfieevans
    Alfie Evans
    ALS
    Armed Forces
    Army
    Baby
    Ben Carson
    Bernie
    Blog
    Bosnia
    CAOC
    #CelebrateWomen
    Christie
    City Council
    Comey
    Cooking
    Crete
    Cruz
    Deep Fry
    Desert Storm
    Donald Trump
    Drug Companies
    Election
    England
    Europe
    Exclusivity
    F-16
    Fanfic
    Fayetteville
    FBI
    FDA
    Fiction
    Fire
    Florida
    Free Market
    Fun
    Germany
    Gilmore
    Government
    Health Care
    Hillary Clinton
    Hobby
    Iraq
    Italy
    John Kasich
    Kevin Williamson
    Korea
    Kuwait
    LANTIRN
    Life
    Local Politics
    Marco Rubio
    Medical Care
    Memoir
    Military
    MIsfitMemo
    #MisfitMemo
    Misfits
    Misfits Politics
    Moms
    Mother's Day
    Narrative
    National Review
    NATO
    Navy
    #NeverTrump
    Patent
    Pharmaceutical
    Philippines
    Phillippines
    Politics
    Raymond
    Reform
    Rex
    Rubio
    Scarcity
    September 11th
    Service
    Ted Cruz
    Thread
    Tweetstorm
    Twitter
    UK
    Water
    Weekly Rewind
    World Cup
    World Trade Center

    RSS Feed

Home

About

Contact​

Copyright © 2016
  MisfitsPolitics
  • Home
  • Misfit Migrants
  • Mess Hall
  • Meet The Misfits
  • Misc. Musings
  • Home
  • Misfit Migrants
  • Mess Hall
  • Meet The Misfits
  • Misc. Musings